RNA Quote, Financials, Valuation and Earnings

Denali Therapeutics has a net margin of -3439.52% compared to Avidity Biosciences's net margin of --. Avidity Biosciences's return on equity of -29.4% beat Denali Therapeutics's return on equity of --.

Avidity Biosciences has a consensus price target of $66.69, signalling upside risk potential of 111.05%. On the other hand Denali Therapeutics has an analysts' consensus of $36.63 which suggests that it could grow by 147.8%. Given that Denali Therapeutics has higher upside potential than Avidity Biosciences, analysts believe Denali Therapeutics is more attractive than Avidity Biosciences.

Avidity Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Denali Therapeutics has a beta of 1.462, suggesting its more volatile than the S&P 500 by 46.172%.

Avidity Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Denali Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avidity Biosciences pays -- of its earnings as a dividend. Denali Therapeutics pays out -- of its earnings as a dividend.

Avidity Biosciences quarterly revenues are $3M, which are larger than Denali Therapeutics quarterly revenues of --. Avidity Biosciences's net income of -$102.3M is higher than Denali Therapeutics's net income of -$114.8M. Notably, Avidity Biosciences's price-to-earnings ratio is -- while Denali Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avidity Biosciences is 323.44x versus 7.13x for Denali Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Dyne Therapeutics has a net margin of -3439.52% compared to Avidity Biosciences's net margin of --. Avidity Biosciences's return on equity of -29.4% beat Dyne Therapeutics's return on equity of --.

Avidity Biosciences has a consensus price target of $66.69, signalling upside risk potential of 111.05%. On the other hand Dyne Therapeutics has an analysts' consensus of $48.21 which suggests that it could grow by 321.09%. Given that Dyne Therapeutics has higher upside potential than Avidity Biosciences, analysts believe Dyne Therapeutics is more attractive than Avidity Biosciences.

Avidity Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Dyne Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Avidity Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dyne Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avidity Biosciences pays -- of its earnings as a dividend. Dyne Therapeutics pays out -- of its earnings as a dividend.

Avidity Biosciences quarterly revenues are $3M, which are larger than Dyne Therapeutics quarterly revenues of --. Avidity Biosciences's net income of -$102.3M is lower than Dyne Therapeutics's net income of -$89.5M. Notably, Avidity Biosciences's price-to-earnings ratio is -- while Dyne Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avidity Biosciences is 323.44x versus -- for Dyne Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals has a net margin of -3439.52% compared to Avidity Biosciences's net margin of -46.06%. Avidity Biosciences's return on equity of -29.4% beat Ionis Pharmaceuticals's return on equity of -103.27%.

Avidity Biosciences has a consensus price target of $66.69, signalling upside risk potential of 111.05%. On the other hand Ionis Pharmaceuticals has an analysts' consensus of $59.42 which suggests that it could grow by 90.75%. Given that Avidity Biosciences has higher upside potential than Ionis Pharmaceuticals, analysts believe Avidity Biosciences is more attractive than Ionis Pharmaceuticals.

Avidity Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ionis Pharmaceuticals has a beta of 0.279, suggesting its less volatile than the S&P 500 by 72.122%.

Avidity Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avidity Biosciences pays -- of its earnings as a dividend. Ionis Pharmaceuticals pays out -- of its earnings as a dividend.

Avidity Biosciences quarterly revenues are $3M, which are smaller than Ionis Pharmaceuticals quarterly revenues of $226.6M. Avidity Biosciences's net income of -$102.3M is higher than Ionis Pharmaceuticals's net income of -$104.3M. Notably, Avidity Biosciences's price-to-earnings ratio is -- while Ionis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avidity Biosciences is 323.44x versus 6.60x for Ionis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Ultragenyx Pharmaceutical has a net margin of -3439.52% compared to Avidity Biosciences's net margin of -80.9%. Avidity Biosciences's return on equity of -29.4% beat Ultragenyx Pharmaceutical's return on equity of -194.36%.

Avidity Biosciences has a consensus price target of $66.69, signalling upside risk potential of 111.05%. On the other hand Ultragenyx Pharmaceutical has an analysts' consensus of $90.21 which suggests that it could grow by 138.53%. Given that Ultragenyx Pharmaceutical has higher upside potential than Avidity Biosciences, analysts believe Ultragenyx Pharmaceutical is more attractive than Avidity Biosciences.

Avidity Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ultragenyx Pharmaceutical has a beta of 0.668, suggesting its less volatile than the S&P 500 by 33.17%.

Avidity Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ultragenyx Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avidity Biosciences pays -- of its earnings as a dividend. Ultragenyx Pharmaceutical pays out -- of its earnings as a dividend.

Avidity Biosciences quarterly revenues are $3M, which are smaller than Ultragenyx Pharmaceutical quarterly revenues of $164.9M. Avidity Biosciences's net income of -$102.3M is higher than Ultragenyx Pharmaceutical's net income of -$133.4M. Notably, Avidity Biosciences's price-to-earnings ratio is -- while Ultragenyx Pharmaceutical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avidity Biosciences is 323.44x versus 6.11x for Ultragenyx Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.